Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04033640
Other study ID # G6PD Brazil
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 27, 2019
Est. completion date December 31, 2019

Study information

Verified date September 2021
Source PATH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Th objectives of this study are: - To determine the performance of G6PD tests in detecting G6PD activity and hemoglobin (Hb) compared to a reference assay - To assess the comprehension of the G6PD test packaging and labelling among intended users - To assess the usability of G6PD test result outputs among intended users


Description:

This is a cross-sectional diagnostic accuracy study that includes both participants and health worker participants. The participant population will be recruited at clinics and through a household survey using an enriched sample of a population with known G6PD status, established through previous epidemiological studies. Clinic staff will take capillary blood samples and conduct two point of care (POC) tests: 1) HemoCue® hemoglobin test, and 2) the investigational Standard Diagnostics (SD) Biosensor STANDARD POC test for glucose-6-phosphate dehydrogenase (G6PD) deficiency. Venous blood will be collected and transferred to a laboratory where reference assays will be performed on venous samples using the Pointe Scientific G6PD Analyzer and hemoglobin tests. The health worker participants will include trained intended users of the G6PD tests. Trained health workers will be surveyed to assess product usability through a questionnaire to assess label and packing comprehension as well as results interpretation.


Recruitment information / eligibility

Status Completed
Enrollment 1754
Est. completion date December 31, 2019
Est. primary completion date December 31, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 2 Years and older
Eligibility 1. Participants with unknown G6PD status Inclusion criteria: - Febrile patients seeking care at the Manaus or Porto Velho clinics - 2 years age or older - Willing to provide informed consent Exclusion criteria - Younger than 2 years of age - Participants who received a blood transfusion in the last 3 months, self report - Unwilling to provide informed consent 2. Participants with known G6PD status Inclusion criteria: - Included in previous G6PD surveys and provided consent to be contacted again - 2 years of age or older - Willing to provide informed consent or assent Exclusion criteria: - Younger than 2 years of age - Participants who received a blood transfusion in the last 3 months, self report - Unwilling to provide informed consent or assent or unavailable during study visit 3. Health workers Inclusion Criteria: - Provides malaria case management at study facility or study site - Considered an intended user of quantitative POC G6PD tests - Trained and proficient in the use of the POC G6PD test - Willing to provide informed consent Exclusion Criteria: - Does not provide malaria case management at study facility or study site - Not considered an intended user of quantitative POC G6PD tests - Not trained or not proficient in the use of the POC G6PD test - Unwilling to provide informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
SD Biosensor STANDARD G6PD Test
The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care (POC) setting. The test is intended to aid in the identification of people with G6PD deficiency. The test is currently not licensed for use in Brazil and is considered an investigational product.
Pointe Scientific Test Kit
The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.
HemoCue System
The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.
Complete blood count (CBC)
In Manaus, hemoglobin concentration was determined by CBC using an automated hematology analyzer (Sysmex KX-21N).

Locations

Country Name City State
Brazil Tropical Medicine Foundation Doctor Heitor Vieira Dourado Manaus Amazonas
Brazil Centro de Pesquisa em Medicina Tropical de Rondônia Porto Velho Rondônia

Sponsors (2)

Lead Sponsor Collaborator
PATH Fundação de Medicina Tropical Dr. Heitor Vieira Dourado

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sensitivity of SD Biosensor STANDARD G6PD Test for Identifying G6PD Deficient Individuals For the purposes of this study, an individual was considered G6PD deficient if they tested positive in the Pointe Scientific assay. A true positive was defined as a participant with = 30% of normal G6PD activity in circulating venous blood determined by the Pointe Scientific test.
Diagnostic sensitivity of the SD Biosensor STANDARD G6PD test is defined as the percentage of participants who tested positive for G6PD deficiency on the reference test who were identified by the test assay as positive, calculated as:
Number of participants who were both test and true positive / (Number of participants who were test and true positive + Number of participants who were test negative but true positive [ie false negative]) * 100%.
Sensitivity of the SD Biosensor STANDARD G6PD test was calculated from both venous and capillary blood samples.
All samples were collected on study day 1
Primary Sensitivity of SD Biosensor STANDARD G6PD Test for Identifying Women With Intermediate G6PD Activity To investigate the performance of the SD Biosensor STANDARD G6PD test to distinguish females with intermediate G6PD activity from females with normal activity, assay sensitivity was determined at a G6PD activity threshold of 70%. A true positive for intermediate G6PD activity in females was defined as G6PD activity between 30 and 70% of normal in circulating venous blood as determined by the Pointe Scientific test.
Sensitivity of the SD Biosensor STANDARD G6PD test is the percentage of women who tested positive for intermediate G6PD activity on the reference test who were identified by the test assay as positive, calculated as:
Number of women who were both test and true positive / (Number of women who were test and true positive + Number of women who were test negative but true positive [ie false negative]) * 100%.
Sensitivity of the SD Biosensor STANDARD G6PD test for identifying females with intermediate G6PD activity was calculated from both venous and capillary blood samples.
All samples were collected on study day 1
Primary Specificity of SD Biosensor STANDARD G6PD Test for Identifying G6PD Deficient Individuals For the purposes of this study, an individual was considered G6PD deficient if they tested positive by the Pointe Scientific assay. A true negative was defined as > 30% of normal G6PD activity in circulating venous blood as determined by the Pointe Scientific test.
Specificity is the percentage of participants who tested negative for G6PD deficiency on the reference test who were identified as negative using the test assay, calculated as:
Number of participants who were both test and true negative / (Number of participants who were test and true negative + Number of participants who were test positive but true negative [ie false positive]) * 100%.
Specificity of the SD Biosensor STANDARD G6PD test was calculated from both venous and capillary blood samples.
All samples were collected on study day 1
Primary Specificity of SD Biosensor STANDARD G6PD Test for Identifying Women With Intermediate G6PD Activity To investigate the performance of the SD Biosensor STANDARD G6PD test to distinguish females with intermediate G6PD activity from females with normal activity, the specificity was determined at a G6PD activity threshold of 70%. A true negative for intermediate G6PD activity in females was defined as G6PD activity > 70% of normal in circulating venous blood as determined by the Pointe Scientific test.
Specificity is the percentage of participants who tested negative for G6PD deficiency on the reference test who were identified as negative using the test assay, calculated as: Number of participants who were both test and true negative / (Number of participants who were test and true negative + Number of participants who were test positive but true negative [ie false positive]) * 100%.
Specificity of the SD Biosensor STANDARD G6PD test was calculated from both venous and capillary blood samples.
All samples were collected on study day 1
Secondary Accuracy Between the SD Biosensor STANDARD G6PD Test Assay and the Pointe Scientific Test Kit Accuracy between the SD Biosensor STANDARD G6PD test assay and the Pointe Scientific G6PD reference assay was calculated as the percent agreement between both G6PD tests, ie, the percentage of participants with the same diagnosis according to both tests (either deficient, intermediate, or normal G6PD levels).
Accuracy of the SD Biosensor STANDARD G6PD test was calculated from both venous and capillary blood samples.
All samples were collected on study day 1
Secondary Accuracy Between the SD Biosensor STANDARD G6PD Test Measure of Hemoglobin and the Reference HemoCue Hemoglobin Test Accuracy between the SD Biosensor STANDARD G6PD test measure of hemoglobin and the HemoCue hemoglobin reference assay was calculated as the percentage agreement between both tests, ie, the percentage of participants with the same diagnosis according to both tests (either non/mild anemia, moderate anemia or severe anemia). All samples were collected on study day 1
Secondary Accuracy Between the SD Biosensor STANDARD G6PD Test Measure of Hemoglobin and the Hemoglobin Measured in a Complete Blood Count Accuracy between the SD Biosensor STANDARD G6PD test measure of hemoglobin and the hemoglobin result from the complete blood count (CBC) reference assay (using an automated hematology analyzer) was calculated as the percentage agreement between both tests, ie, the percentage of participants with the same diagnosis according to both tests (either non/mild anemia, moderate anemia or severe anemia). Complete blood counts were only conducted for participants enrolled at the site in Manaus. All samples were collected on study day 1
Secondary Median G6PD Values Measured by the SD Biosensor STANDARD G6PD Test for Venous and Capillary Blood Samples All samples were collected on study day 1
Secondary Number of Participants Who Met Acceptance Criteria for Label Comprehension After completing training, health worker participants were asked to complete a questionnaire to assess their comprehension of the test label. The questionnaire consisted of 13 multiple-choice questions with mutually exclusive options and a single correct answer focused on aspects of the product label including key warnings, limitations, and restrictions as well as the proper test procedure.
Acceptance (success) criterion for label comprehension was defined as at least 85% correct responses (11 out of 13 possible points).
Day 1
Secondary Number of Participants Who Met Acceptance Criteria for Accurate Results Interpretation After completing training, health worker participants were asked to complete a questionnaire to assess their ability to interpret the test result outputs. The questionnaire consisted of seven short-answer questions (5 valid results, 2 invalid results) focused on the participant's ability to read the results screen, record the simulated G6PD and hemoglobin quantitative results, and classify the results as normal, intermediate, deficient, or invalid.
For each valid result, three points were possible: (one for G6PD result transcription, one for hemoglobin result transcription, and one for result interpretation) and for each invalid result, one point was possible, resulting in a total of 17 possible points.
Acceptance (success) criterion for results interpretation was defined as at least 85% correct responses (15 out of 17 possible points).
Day 1
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05096702 - Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil
Recruiting NCT04073953 - Primaquine Enantiomers in G6PD Deficient Human Volunteers Phase 1
Completed NCT02434952 - Safety and Tolerability of Low Dose Primaquine Phase 4
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Completed NCT04081272 - Effect of G6PD Deficiency on Red Blood Cell Storage
Completed NCT04146246 - Comparative Evaluation of the FINDER Instrument and FINDER G6PD Cartridge in Adults and Neonates
Recruiting NCT05026489 - G6PD Deficiency in Infarction Patients in Shaanxi Province
Terminated NCT03337152 - Assessing a Risk Model for G6PD Deficiency Phase 4
Completed NCT05753150 - Operational Feasibility of Appropriate Plasmodium Vivax Radical Cure After G6PD Testing in Thailand
Completed NCT04010695 - Validation of Diagnostics to Identify Glucose-6-phosphate Dehydrogenase Activity in the US N/A
Completed NCT01931644 - At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Active, not recruiting NCT03529396 - Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in G6PD Deficient Patients Phase 2
Recruiting NCT05874271 - Short Course Primaquine for the Radical Cure of P. Vivax - Papua New Guinea N/A
Recruiting NCT04088513 - Safety and Efficacy of Aspirin in Stroke Patients With Glucose-6-phosphate Dehydrogenase Deficiency (SAST) Phase 4
Not yet recruiting NCT05571748 - Oxidative Stress, Carbohydrate Metabolism Disorders and G6PD Deficiency N/A
Not yet recruiting NCT02937376 - Effects of N-acetyl Cystein (NAC) Supplementation in G6PD Deficient Individuals After Acute Exercise Early Phase 1
Completed NCT02937363 - Effects of Alpha Lipoic Acid Supplementation in G6PD Deficient Individuals After Acute Exercise N/A
Recruiting NCT05879224 - Short Course Primaquine for the Radical Cure of P. Vivax Malaria - Indonesia N/A
Completed NCT04054661 - Validation of a Diagnostic Test for Glucose-6-phosphate Dehydrogenase (G6PD) Deficiency in Anti-coagulated Blood N/A